@prefix : <http://semanticscholar.org/cv-research/> .
@prefix dc: <http://purl.org/dc/terms/> .
@prefix fhir_link: <http://hl7.org/fhir/link/> .
@prefix ncit: <http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix sso: <http://semanticscholar.org/cv-research/> .
@prefix whocv: <http://semanticscholar.org/cv-research/WHO#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<http://fhircat.org/cord-19/metadata/cb6ac0e6f129a47a228c217485d17d091c8c2421> fhir_link: <https://fhircat.org/cord-19/fhir/Non-comercial/cb6ac0e6f129a47a228c217485d17d091c8c2421> ;
    dc:abstract "Pre-existing immunity against human adenovirus (HAd) serotype 5 derived vector in the human population is widespread, thus hampering its clinical use. Various components of the immune system, including neutralizing antibodies (nAbs), Ad specific T cells and type I IFN activated NK cells, contribute to dampening the efficacy of Ad vectors in individuals with pre-existing Ad immunity. In order to circumvent pre-existing immunity to adenovirus, numerous strategies, such as developing alternative Ad serotypes, varying immunization routes and utilizing prime-boost regimens, are under pre-clinical or clinical phases of development. However, these strategies mainly focus on one arm of pre-existing immunity. Selection of alternative serotypes has been largely driven by the absence in the human population of nAbs against them with little attention paid to cross-reactive Ad specific T cells. Conversely, varying the route of immunization appears to mainly rely on avoiding Ad specific tissue-resident T cells. Finally, prime-boost regimens do not actually circumvent pre-existing immunity but instead generate immune responses of sufficient magnitude to confer protection despite pre-existing immunity. Combining the above strategies and thus taking into account all components regulating pre-existing Ad immunity will help further improve the development of Ad vectors for animal and human use." ;
    dc:creator "['Fausther-Bovendo, Hugues', 'Kobinger, Gary P']" ;
    dc:identifier <http://dx.doi.org/10.4161/hv.29594>,
        <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443060>,
        <https://www.ncbi.nlm.nih.gov/pubmed/25483662> ;
    dc:issued "2014-01-01"^^xsd:date ;
    dc:license "CC BY-NC" ;
    dc:title "Pre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what's important?" ;
    sso:has_full_text "True" ;
    sso:journal "Hum Vaccin Immunother" ;
    sso:sha "cb6ac0e6f129a47a228c217485d17d091c8c2421" ;
    sso:source_x "PMC" .